Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $163.0M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +23 vs. previous quarter
- 100
- 13F valueReported value at the end of Q2 2026
- $545.7M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $102.5M
- +65.2% year over year
- Net income, FY2025
- -$191.1M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- $9.10M
- −6.1% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $191.1M (186.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.26M
- Shares sold short
- Change
- +296.6K
- +15.1% vs. previous
- Days to cover
- 6.26
- At average daily volume
Superinvestors holding STRO, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding STRO at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Sutro Biopharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 2025 (view filing) | Oct 15 | 1 day | Pauling DavidChief Admin. Ofcr. & GC | PPurchase | +12.5K | $0.80 | +$10.0K | +21.1%71.7K after | |
| Oct 16, 2025 (view filing) | Oct 15 | 1 day | Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER | PPurchase | +17.0K | $0.80 | +$13.6K | +31.0%71.8K after | |
| Oct 16, 2025 (view filing) | Oct 15 | 1 day | Chung JaneChief Executive Officer | PPurchase | +12.5K | $0.80 | +$10.0K | +11.3%122.8K after | |
| Oct 16, 2025 (view filing) | Oct 15 | 1 day | Chow Gregory K.CFO | PPurchase | +19.8K | $0.81 | +$16.0K | New position19.8K after | |
| Oct 16, 2025 (view filing) | Oct 15 | 1 day | Matsui ConnieDirector | PPurchase | +50.0K | $0.80 | +$40.0K | New position50.0K after | |
| Jan 31, 2024 (view filing) | Jan 29 | 2 days | Vasquez NickiCHIEF PORT. STRAT & ALNCE OFCR | SSale | −12.2K | $5.00 | −$60.9K | −48.8%12.8K after | 10b5-1 |
| Aug 29, 2023 (view filing) | Aug 28 | 1 day | Shtylla BrunildaChief Business Officer | SSale | −15.4K | $4.71 | −$72.7K | −100.0%0 after | |
| Aug 28, 2023 (view filing) | Aug 25 | 3 days | Shtylla BrunildaChief Business Officer | SSale | −11.6K | $4.59 | −$53.3K | −47.3%12.9K after | |
| Mar 15, 2022 (view filing) | Mar 14 | 1 day | Newell William JCEO | PPurchase | +10.0K | $7.75 | +$77.5K | +9.4%116.5K after | |
| Sep 28, 2021 (view filing) | Sep 28 | Same day | Vasquez NickiChief Port. Strat & Alnce Ofcr | SSale | −3.91K | $18.62 | −$72.7K | −34.9%7.27K after |
Top 10 13F holders, Q2 2026
See all 100 holdersThe largest institutional positions in Sutro Biopharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 1,304,846 | $43.3M | 0.67% | +589,539+82.4% | Added |
| BVF Inc | 1,251,788 | $41.6M | 1.06% | 00.0% | Unchanged |
| Affinity Asset Advisors, LLC | 1,172,487 | $38.9M | 1.90% | +102,968+9.6% | Added |
| BlackRock, Inc. | 1,122,655 | $37.3M | 0.00% | +889,971+382.5% | Added |
| Samsara BioCapital, LLC | 1,062,872 | $35.3M | 2.90% | 00.0% | Unchanged |
| Kynam Capital Management, LP | 872,558 | $29.0M | 1.60% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 743,944 | $24.7M | 0.47% | −57,200−7.1% | Reduced |
| Balyasny Asset Management LLC | 711,162 | $23.6M | 0.04% | +245,370+52.7% | Added |
| Vanguard Capital Management LLC | 694,219 | $23.0M | 0.00% | −26,223−3.6% | Reduced |
| Eventide Asset Management, LLC | 585,262 | $19.4M | 0.26% | −130,045−18.2% | Reduced |
Holders of 5% or more of STRO
See all 8 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Sutro Biopharma, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | 13G/A | 7.90%1.30M shares | +2.50 ppfrom 5.40% | Apr 21, 20262 filings | Aug 14, 2026 | SEC |
| Biotechnology Value Fund L P | 13G | 7.60%1.25M shares | – | Feb 12, 20215 filings | Feb 18, 2026 | SEC |
| Affinity Asset Advisors, LLC | 13G/A | 6.50%1.07M shares | −2.30 ppfrom 8.80% | Oct 23, 20253 filings | May 14, 2026 | SEC |
| BlackRock, Inc. | 13G | 6.40%1.07M shares | New | Jul 30, 20261 filing | Jul 30, 2026 | SEC |
| Samsara BioCapital, L.P. | 13G | 6.40%1.06M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |